Do analysts prefer BFRG or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BFRG or PPCB more profitable?

Propanc Biopharma's return on equity of -151.28% beat Bullfrog AI's return on equity. Company Net Margins Return on Equity Return on Assets Bullfrog AI N/A -217.80% -174.57% Propanc Biopharma N/A -151.28% -109.53%

Which has preferable valuation & earnings, CVKD or PPCB?

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadrenal Therapeutics N/A N/A -$13.24M -$5.63 N/A Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A

Is CVKD or PPCB more profitable?

Propanc Biopharma's return on equity of -151.28% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cadrenal Therapeutics N/A -411.03% -275.61% Propanc Biopharma N/A -151.28% -109.53%

Does the media prefer CVKD or PPCB?

In the previous week, Cadrenal Therapeutics had 2 more articles in the media than Propanc Biopharma. MarketBeat recorded 6 mentions for Cadrenal Therapeutics and 4 mentions for Propanc Biopharma. Propanc Biopharma's average media sentiment score of 1.22 beat Cadrenal Therapeutics' score of -0.16 indicating that Propanc Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadrenal Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BFRI or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to BFRI or PPCB?

In the previous week, Propanc Biopharma had 1 more articles in the media than Biofrontera. MarketBeat recorded 4 mentions for Propanc Biopharma and 3 mentions for Biofrontera. Propanc Biopharma's average media sentiment score of 1.22 beat Biofrontera's score of 0.91 indicating that Propanc Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer FNCH or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, FNCH or PPCB?

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A

Is FNCH or PPCB more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Propanc Biopharma N/A -151.28% -109.53%

Do analysts recommend MTVA or PPCB?

MetaVia presently has a consensus price target of $20.00, indicating a potential upside of 1,049.43%. Given MetaVia's stronger consensus rating and higher possible upside, research analysts clearly believe MetaVia is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, MTVA or PPCB?

MetaVia is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$5.19 N/A Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A

Is MTVA or PPCB more profitable?

Propanc Biopharma's return on equity of -151.28% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -172.92% -89.39% Propanc Biopharma N/A -151.28% -109.53%

Does the media prefer MTVA or PPCB?

In the previous week, MetaVia had 1 more articles in the media than Propanc Biopharma. MarketBeat recorded 5 mentions for MetaVia and 4 mentions for Propanc Biopharma. Propanc Biopharma's average media sentiment score of 1.22 beat MetaVia's score of 0.29 indicating that Propanc Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Propanc Biopharma (PPCB) Competitors

$2.27 -0.16 (-6.58%)

Closing price 04:00 PM Eastern

Extended Trading

$2.07 -0.20 (-8.81%)

As of 07:59 PM Eastern

Compare

PPCB vs. BFRG, CVKD, BFRI, FNCH, and MTVA

Should you buy Propanc Biopharma stock or one of its competitors? MarketBeat compares Propanc Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Propanc Biopharma include Bullfrog AI (BFRG), Cadrenal Therapeutics (CVKD), Biofrontera (BFRI), Finch Therapeutics Group (FNCH), and MetaVia (MTVA). These companies are all part of the "pharmaceutical products" industry.

How does Propanc Biopharma compare to Bullfrog AI?

Bullfrog AI (NASDAQ:BFRG) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

In the previous week, Propanc Biopharma had 3 more articles in the media than Bullfrog AI. MarketBeat recorded 4 mentions for Propanc Biopharma and 1 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 1.89 beat Propanc Biopharma's score of 1.22 indicating that Bullfrog AI is being referred to more favorably in the media.

Company	Overall Sentiment
Bullfrog AI	Very Positive
Propanc Biopharma	Positive

1.0% of Bullfrog AI shares are owned by institutional investors. 25.2% of Bullfrog AI shares are owned by insiders. Comparatively, 28.5% of Propanc Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bullfrog AI has a beta of -2.89, indicating that its stock price is 389% less volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.48, indicating that its stock price is 248% more volatile than the broader market.

Propanc Biopharma's return on equity of -151.28% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-217.80%	-174.57%
Propanc Biopharma	N/A	-151.28%	-109.53%

Bullfrog AI has higher revenue and earnings than Propanc Biopharma. Bullfrog AI is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$120K	95.48	-$6.50M	-$0.54	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

Summary

Bullfrog AI and Propanc Biopharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Propanc Biopharma compare to Cadrenal Therapeutics?

Cadrenal Therapeutics (NASDAQ:CVKD) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

Propanc Biopharma's return on equity of -151.28% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-411.03%	-275.61%
Propanc Biopharma	N/A	-151.28%	-109.53%

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

Cadrenal Therapeutics has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.48, indicating that its stock price is 248% more volatile than the broader market.

Cadrenal Therapeutics presently has a consensus price target of $13.00, suggesting a potential upside of 251.35%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cadrenal Therapeutics is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Cadrenal Therapeutics had 2 more articles in the media than Propanc Biopharma. MarketBeat recorded 6 mentions for Cadrenal Therapeutics and 4 mentions for Propanc Biopharma. Propanc Biopharma's average media sentiment score of 1.22 beat Cadrenal Therapeutics' score of -0.16 indicating that Propanc Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadrenal Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 26.1% of Cadrenal Therapeutics shares are owned by insiders. Comparatively, 28.5% of Propanc Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Cadrenal Therapeutics beats Propanc Biopharma on 7 of the 12 factors compared between the two stocks.

How does Propanc Biopharma compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biofrontera has higher revenue and earnings than Propanc Biopharma. Biofrontera is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.27	-$10.54M	-$0.97	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

10.1% of Biofrontera shares are held by institutional investors. 4.8% of Biofrontera shares are held by company insiders. Comparatively, 28.5% of Propanc Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Propanc Biopharma has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Propanc Biopharma's return on equity of -151.28% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
Propanc Biopharma	N/A	-151.28%	-109.53%

Biofrontera has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.48, suggesting that its stock price is 248% more volatile than the broader market.

In the previous week, Propanc Biopharma had 1 more articles in the media than Biofrontera. MarketBeat recorded 4 mentions for Propanc Biopharma and 3 mentions for Biofrontera. Propanc Biopharma's average media sentiment score of 1.22 beat Biofrontera's score of 0.91 indicating that Propanc Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biofrontera beats Propanc Biopharma on 7 of the 13 factors compared between the two stocks.

How does Propanc Biopharma compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.48, suggesting that its stock price is 248% more volatile than the broader market.

Finch Therapeutics Group's return on equity of -69.14% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Propanc Biopharma	N/A	-151.28%	-109.53%

21.8% of Finch Therapeutics Group shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 28.5% of Propanc Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Propanc Biopharma had 4 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 4 mentions for Propanc Biopharma and 0 mentions for Finch Therapeutics Group. Propanc Biopharma's average media sentiment score of 1.22 beat Finch Therapeutics Group's score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Propanc Biopharma	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

Summary

Finch Therapeutics Group and Propanc Biopharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Propanc Biopharma compare to MetaVia?

MetaVia (NASDAQ:MTVA) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

MetaVia is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

Propanc Biopharma's return on equity of -151.28% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-172.92%	-89.39%
Propanc Biopharma	N/A	-151.28%	-109.53%

1.4% of MetaVia shares are owned by institutional investors. 0.6% of MetaVia shares are owned by insiders. Comparatively, 28.5% of Propanc Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

MetaVia presently has a consensus price target of $20.00, indicating a potential upside of 1,049.43%. Given MetaVia's stronger consensus rating and higher possible upside, research analysts clearly believe MetaVia is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, MetaVia had 1 more articles in the media than Propanc Biopharma. MarketBeat recorded 5 mentions for MetaVia and 4 mentions for Propanc Biopharma. Propanc Biopharma's average media sentiment score of 1.22 beat MetaVia's score of 0.29 indicating that Propanc Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MetaVia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MetaVia has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.48, meaning that its share price is 248% more volatile than the broader market.

Summary

MetaVia beats Propanc Biopharma on 8 of the 12 factors compared between the two stocks.

Get Propanc Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPCB vs. The Competition

Export

Metric	Propanc Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.54M	$3.37B	$6.49B	$11.98B
Dividend Yield	N/A	2.32%	2.67%	5.57%
P/E Ratio	N/A	19.65	23.85	24.45
Price / Sales	N/A	312.51	572.24	136.74
Price / Cash	N/A	120.36	43.20	54.62
Price / Book	0.08	8.32	10.66	6.80
Net Income	-$58.92M	$23.89M	$3.56B	$337.76M
7 Day Performance	56.55%	0.94%	0.05%	2.08%
1 Month Performance	0.33%	-1.16%	0.37%	3.16%
1 Year Performance	-98.87%	41.51%	22.73%	27.78%

Propanc Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPCB Propanc Biopharma	1.4034 of 5 stars	$2.27 -6.6%	N/A	-98.8%	$5.54M	N/A	N/A	1	Positive News Buyback Announcement Short Interest Decrease Gap Down
BFRG Bullfrog AI	1.2021 of 5 stars	$0.67 -0.1%	N/A	-66.0%	$12.43M	$116.67K	N/A	4	Positive News Gap Down
CVKD Cadrenal Therapeutics	2.9184 of 5 stars	$4.21 -5.2%	$13.00 +208.8%	-73.1%	$12.08M	N/A	N/A	4	High Trading Volume
BFRI Biofrontera	1.593 of 5 stars	$0.93 -0.5%	N/A	+36.7%	$11.90M	$41.71M	N/A	70
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPCB) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Propanc Biopharma (PPCB) Competitors

PPCB vs. BFRG, CVKD, BFRI, FNCH, and MTVA

How does Propanc Biopharma compare to Bullfrog AI?

Summary

How does Propanc Biopharma compare to Cadrenal Therapeutics?

Summary

How does Propanc Biopharma compare to Biofrontera?

Summary

How does Propanc Biopharma compare to Finch Therapeutics Group?

Summary

How does Propanc Biopharma compare to MetaVia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB vs. The Competition

Propanc Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Propanc Biopharma (PPCB) Competitors

PPCB vs. BFRG, CVKD, BFRI, FNCH, and MTVA

How does Propanc Biopharma compare to Bullfrog AI?

Does the media refer more to BFRG or PPCB?

Do insiders & institutionals believe in BFRG or PPCB?

Do analysts prefer BFRG or PPCB?

Which has more risk and volatility, BFRG or PPCB?

Is BFRG or PPCB more profitable?

Which has stronger valuation and earnings, BFRG or PPCB?

Summary

How does Propanc Biopharma compare to Cadrenal Therapeutics?

Is CVKD or PPCB more profitable?

Which has preferable valuation & earnings, CVKD or PPCB?

Which has more risk and volatility, CVKD or PPCB?

Do analysts rate CVKD or PPCB?

Does the media prefer CVKD or PPCB?

Do insiders and institutionals hold more shares of CVKD or PPCB?

Summary

How does Propanc Biopharma compare to Biofrontera?

Do analysts rate BFRI or PPCB?

Which has higher valuation & earnings, BFRI or PPCB?

Do insiders & institutionals have more ownership in BFRI or PPCB?

Is BFRI or PPCB more profitable?

Which has more volatility and risk, BFRI or PPCB?

Does the media refer more to BFRI or PPCB?

Summary

How does Propanc Biopharma compare to Finch Therapeutics Group?

Which has more volatility and risk, FNCH or PPCB?

Is FNCH or PPCB more profitable?

Do insiders and institutionals believe in FNCH or PPCB?

Does the media prefer FNCH or PPCB?

Do analysts prefer FNCH or PPCB?

Which has better valuation and earnings, FNCH or PPCB?

Summary

How does Propanc Biopharma compare to MetaVia?

Which has better earnings and valuation, MTVA or PPCB?

Is MTVA or PPCB more profitable?

Do insiders & institutionals believe in MTVA or PPCB?

Do analysts recommend MTVA or PPCB?

Does the media prefer MTVA or PPCB?

Which has more volatility and risk, MTVA or PPCB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB vs. The Competition

Propanc Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools